ArticleAME clinical trials review2026

Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial.

Daniel K Reef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.